How pharmacy acquisition finance works
Pharmacy acquisition loans are structured around the recurring NHS contract income and covenanted on the deal, not underwritten like a standard retail loan. The numbers depend on the lender and the deal: this post explains the mechanics at method level so you understand what a lender is testing and why, before you approach one. For the prior question of whether you can afford the purchase at all, see the companion post on first-time pharmacy buyer finance and affordability.
The fundamental difference from a generic business loan is that a dispensing pharmacy earns most of its income under the Community Pharmacy Contractual Framework: reimbursement for dispensing plus remuneration for services. That income is contract-driven and recurring in a way that most retail businesses are not, and lenders pricing pharmacy acquisition debt treat it differently because of that.
Loan structure at method level: term, security, and guarantees
Pharmacy acquisition finance is specialist commercial lending. The structure of any facility will depend on the lender, the deal, and the buyer's financial position. What follows is a description of the common structural features at method level; no rates, loan-to-value ratios, or term lengths are stated here because those are lender-specific and change with market conditions.
Security
Lenders typically take security over the assets being financed. In a share purchase, security sits over the shares and often over the underlying business assets as well. In an asset purchase, security attaches to the acquired assets directly. The choice of deal structure changes the security picture, which is one of several reasons the share-versus-asset decision matters before any lender conversation starts. The full structuring comparison is covered in the share versus asset purchase guide.
Personal guarantees
First-time pharmacy buyers should expect a personal guarantee to be required alongside the company or partnership borrowing. A guarantee means the individual borrower (or guarantors) stands behind the debt if the business cannot service it. The scope and terms of guarantees vary by lender and deal. They are a standard feature of pharmacy acquisition lending and not a signal of lender concern about the deal quality on their own.
What the lender is not doing
A pharmacy acquisition lender is not writing a retail mortgage secured on bricks and mortar as the primary underwriting story. The NHS contract, the dispensing volume, and the adjusted EBITDA carry the underwriting case. Goodwill dominates pharmacy pricing (it is the NHS contract and item volume the buyer is acquiring), but goodwill is intangible. That is why lenders focus on the income the goodwill produces, not the balance-sheet value of the goodwill itself.
What a covenant is, and why lenders use them
A financial covenant is a contractual condition written into the loan agreement that the borrower must satisfy on an ongoing basis throughout the loan term, not just at drawdown. Covenants are the lender's mechanism for monitoring the health of the business that is servicing the debt, between the point of lending and the point of repayment.
For a pharmacy acquisition, common covenant types include:
| Covenant type | What it tests in plain English | Pharmacy-specific angle |
|---|---|---|
| EBITDA covenant | Earnings before interest, tax, depreciation and amortisation must stay above a minimum level set by the lender | Directly linked to how the pharmacy was valued; the lender is checking that the income surplus that justified the purchase price is still there |
| Debt service cover ratio | Cash available to service debt (capital and interest) as a multiple of the annual debt service obligation | Sensitive to Drug Tariff margin movements because gross margin is set centrally and retrospectively adjusted |
| Leverage covenant | Total debt as a ratio of EBITDA; controls how loaded the business is | Relevant where the buyer is funding working capital as well as the acquisition, or where a staged payment structure exists |
| Minimum income / turnover | NHS dispensing turnover must not fall below a threshold | Item volume is the underlying driver; a contract variation or significant patient list movement affects this covenant directly |
Specific ratios and thresholds are lender-specific. The table describes the types and their pharmacy logic, not the numbers a particular lender would set.
Covenants are tested on a schedule, most commonly quarterly or annually based on the management accounts or the filed accounts. Lenders may also include information covenants requiring the borrower to deliver accounts, dispensing data, or other management information within agreed timeframes. Missing an information covenant is itself a breach even if the financial numbers are healthy.
The EBITDA covenant explained
EBITDA (earnings before interest, tax, depreciation and amortisation) is the most common covenant anchor in pharmacy acquisition lending because it is the metric most closely linked to how the business was valued and how debt-service capacity was projected when the lender approved the loan.
What EBITDA measures
EBITDA strips out the financing structure (interest), the tax position, and the non-cash charges (depreciation and amortisation) to give a measure of operating earnings from the business itself. For a dispensing pharmacy, those operating earnings are driven by the NHS contract income after staff, premises, and operating costs.
Why "adjusted" EBITDA matters in a pharmacy deal
Raw EBITDA from the accounts may not reflect the true earning capacity of the pharmacy on an arm's-length basis. Common adjustments include:
- Adding back an owner's salary above a market-rate management cost (because the buyer is paying themselves differently from the selling owner).
- Removing one-off costs or income that will not recur under new ownership.
- Normalising for any period where the previous owner's health or absence suppressed item volume.
- Stripping out costs the seller was running through the business that the buyer will not.
The adjusted EBITDA is the number the buyer and their specialist adviser present to a lender as the verified income surplus. It is also the number that underpins the valuation methodology (valuation stays method-level, on a multiple of adjusted EBITDA and pence-per-item; no specific multiple is quoted here because the multiple is deal-specific and lender-specific).
The link between valuation and covenant is direct: if the lender valued the lending on an adjusted EBITDA multiple, the EBITDA covenant protects the same metric throughout the loan term. A fall in adjusted EBITDA means the business would be worth less under the same multiple, so the lender's security position has weakened.
The covenant threshold
The covenant threshold (the minimum EBITDA level you must maintain) is set by the lender at the time of lending and will be stated in the facility agreement. It is not a published industry standard and varies by lender, deal size, and the lender's assessment of the income risk in this particular pharmacy.
What happens if the covenant is breached
A covenant breach triggers a notification obligation to the lender and a conversation. The outcome depends on the facility agreement and the lender's assessment of the cause. Common responses include:
- Waiver: the lender waives the breach for a defined period, typically with conditions attached.
- Remedy period: the borrower is given time to restore the metric, often with a requirement to provide a plan.
- Margin step-up: the interest margin increases as a cost of breach.
- Accelerated repayment: in persistent or material cases, the lender may call in the facility early.
The practical risk in a pharmacy is that a Drug Tariff or Category M adjustment suppresses gross margin in a quarter where income and costs are otherwise stable. That is why monitoring covenant headroom throughout the year (not just at year-end) is part of the ongoing financial management of the acquisition.
How the NHS income and margin story shape lender appetite
What a specialist pharmacy lender reads is fundamentally different from what a high-street business lender looks at. The table below summarises the difference:
| What a generic business lender might look at | What a pharmacy acquisition lender reads instead | Why it matters |
|---|---|---|
| Total sales turnover from the till | NHS contract income: reimbursement plus remuneration under the CPCF | Pharmacy income is contract-driven, not till-driven; NHS income is recurring and regulated in a way retail sales are not |
| Year-end accounts gross profit | Adjusted EBITDA, with Drug Tariff and Category M adjustments normalised | Gross margin is set centrally and retrospectively adjusted via the Drug Tariff; the reported margin in any single year may not reflect the normalised position |
| Current-year cash position | FP34 payment cycle and NHSBSA advance on account | Prescriptions are submitted monthly; payment arrives roughly two months later; the lag is structural, not a sign of cash weakness |
| VAT-inclusive retail revenue | VAT-split income: zero-rated dispensing versus standard-rated OTC and services | The pharmacy is a VAT-mixed business; reading VAT-inclusive revenue as a single number distorts the real income picture for both lender and buyer |
| Item-level retail data | Dispensing item volume over time (monthly, quarterly, year-on-year) | Item volume drives reimbursement income and benchmarks the pharmacy's NHS contract utilisation; a declining item trend signals contract and covenant risk |
Service income under Pharmacy First and similar schemes is a growing separately accounted revenue line. Lenders are increasingly factoring it in, but it is not yet as predictable as core dispensing income and may be weighted differently in covenant calculations.
Finance-ready accounts and covenant headroom
The quality of the accounts you bring to a lender conversation determines how much uncertainty the lender builds into its covenant thresholds. Poor-quality accounts (NHS income mixed with OTC retail, Drug Tariff adjustments not reconciled, VAT mix unclear) force the lender to apply conservative assumptions, which typically means tighter covenant headroom than the business's actual position warrants.
Finance-ready accounts for a pharmacy acquisition do the following:
- Separate NHS reimbursement income from OTC retail so the contract-driven recurring income line is clearly evidenced.
- Reconcile NHSBSA payments to the FP34 submissions for each period, showing the advance-on-account structure and the payment lag.
- Account for Drug Tariff and Category M retrospective adjustments in the period they relate to, not the period the payment or clawback lands.
- Present the VAT-mixed position correctly, distinguishing zero-rated dispensing from standard-rated sales.
- Calculate adjusted EBITDA with documented add-backs, consistent across all periods presented to the lender.
The same accounts structure that makes a lender confident at drawdown also makes covenant monitoring straightforward throughout the loan term. When the lender tests your EBITDA covenant from the management accounts, the calculation should be reproducible from the same methodology used at inception. Inconsistency between periods is a red flag that lenders treat as a covenant risk in itself.
The companion post on first-time pharmacy buyer finance and affordability covers the deposit, loan, and post-tax cash-cover arithmetic that sits before the lender conversation. That affordability arithmetic feeds into the same adjusted EBITDA that a covenant will later test.
The pharmacy purchase affordability calculator models the scenario in structured form as an estimate. It is a starting point for the specialist review, not a lending decision.
If you are approaching the purchase of a pharmacy and want a clear picture of how the financial due-diligence process fits alongside the loan mechanics, the pharmacy financial due diligence guide covers that in detail.
What a specialist prepares before you approach a lender
Approaching a pharmacy acquisition lender without finance-ready accounts and a clear adjusted EBITDA analysis puts the buyer in a weak negotiating position. The lender's questions about covenant structure are directly driven by the clarity of the information pack. A well-prepared pack reduces lender uncertainty, which is the main lever the buyer controls before the rate and covenant negotiation starts.
Before any lender conversation, a specialist will typically prepare:
- A reconciled income analysis separating NHS contract income from retail, with NHSBSA payment data matched to FP34 submissions.
- An adjusted EBITDA calculation with documented add-backs for owner-specific costs, one-off items, and Drug Tariff timing differences, consistent across at least three years of accounts.
- A working-capital model that accounts for the FP34 payment lag of roughly two months in the first months of ownership.
- A VAT-mix summary evidencing the zero-rated dispensing proportion, the standard-rated OTC and service income split, and the input VAT reclaim position.
- A covenant sensitivity analysis showing how much the EBITDA can fall before the proposed covenant threshold is breached, and what margin volatility scenarios (Drug Tariff adjustments, item volume movements) could get there.
The loan mechanics described here apply to a dispensing pharmacy in England. The NHS contract terms (CPCF, Drug Tariff, Pharmacy First) are England-specific; contract variants in Scotland, Wales and Northern Ireland follow different frameworks and are a post-launch content lane on this site.
For help preparing the accounts and adjusted EBITDA analysis before a lender conversation, see the pharmacy purchase accounting service or speak to the team via the buying a pharmacy hub.